Example
Guarda il video
Nel cuore si accumulano storie e ricordi. Ma se vai spesso in affanno e avverti sintomi come affaticamento e capogiri, forse il tuo cuore sta cercando di dirti qualcosa.
Example
Example
Example
Example
1.Rapezzi, Claudio et al. “Transthyretin-related amyloidoses and the heart: a clinical overview.” Nature Reviews Cardiology vol. 7, 7 (2010): 398-408. doi: 10.1038/nrcardio.2010.67.
2.Ruberg, Frederick L. et al. “Transthyretin (TTR) cardiac amyloidosis.” Circulation vol. 126, 10 (2012): 1286-1300. doi: 10.1161/CIRCULATIONAHA.111.078915.
3.Arbustini, Eloisa et al. “Proteine che "fibrillano": l'amiloidosi. Nuove speranze per una malattia che il cardiologo deve conoscere.” Giornale Italiano di Cardiologia vol. 3, 6 (2002): 590-597.
4.Rapezzi, Claudio et al. “Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.” European Heart Journal vol. 34, 7 (2013): 520-528. doi: 10.1093/eurheartj/ehs123.
5.Nativi-Nicolau, Jose et al. “Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.” Current Opinion in Cardiology vol. 33, 5 (2018): 571-579.
doi: 10.1097/HCO.0000000000000547.
6.American Heart Association “Answers by Heart. Cardiovascular Conditions.” (2019). Available at: https://www.heart.org/-/media/files/health-topics/answers-by-heart/what-is-attrcm.pdf. Accessed October 2022.
7.Dungu, Jason N. et al. “Cardiac transthyretin amyloidosis.” Heart vol. 98, 21 (2012): 1546-1554.
doi: 10.1136/heartjnl-2012-301924.
8.Falk, Rodney H. “Diagnosis and management of the cardiac amyloidoses.” Circulation vol. 112, 13 (2005): 2047-2060. doi: 10.1161/CIRCULATIONAHA.104.489187.
9.Ando, Yukio et al. “Guideline of transthyretin-related hereditary amyloidosis for clinicians.” Orphanet J Rare Dis vol. 8, 31 (2013): 1-18. doi: 10.1186/1750-1172-8-31.
10.Gillmore, Julian D et al. “Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.” Circulation vol. 14, 133 (2016): 2404-2412.
doi: 10.1161/CIRCULATIONAHA.116.021612.
11.Gendre, Thierry et al. “Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.” Clinical Autonomic Research vol. 29, Suppl. 1 (2019): 25-31. doi: 10.1007/s10286-019-00624-w.
12.Legge 502, 1992 - Allegato 7. Supplemento ordinario n°15 alla Gazzetta Ufficiale, Serie Generale - n°65
13.Definizione e aggiornamento dei Livelli Essenziali di Assistenza, di cui all'articolo 1, comma 7, del Decreto legislativo 30 dicembre 1992, n°502 (17A02015)
14.Decreto legislativo 29 aprile 1998, n°124
15.Padlan, Eduardo A. “Anatomy of the antibody molecule.” Molecular Immunology vol. 31, 3 (1994): 169-217. doi: 10.1016/0161-5890(94)90001-9.
16.Garcia-Pavia, Pablo et al. “Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.” European journal of heart failure vol. 23,4 (2021): 512-526. doi:10.1002/ejhf.2140
17.González-López, Esther et al. “Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.” Revista espanola de cardiologia (English ed.) vol. 70,11 (2017): 991-1004. doi:10.1016/j.rec.2017.05.03
PP-UNP-ITA-1215